XML 55 R37.htm IDEA: XBRL DOCUMENT
v3.25.4

Condensed Financial Information (Parent Company Only) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Condensed Financial Information Disclosure [Abstract] |
Schedule of Condensed Balance Sheets Information |
| December 31, 2025 |  | December 31, 2024
Assets |  |  |
Investment in subsidiary | $ | 520,283 |  |  | $ | 425,033 |
Total assets | $ | 520,283 |  |  | $ | 425,033 |
Liabilities and Stockholders' Equity |  |  |
Due to subsidiary | 16,061 |  |  | 1,762 |
Accrued expenses | 1,769 |  |  | 1,992 |
Long-term debt, net of debt issuance costs | 323,176 |  |  | 321,428 |
Total liabilities | $ | 341,006 |  |  | $ | 325,182 |
Commitments and Contingencies (Note 14) |  |  |
Stockholders' Equity: |  |  |
Preferred stock, $.001 par value; 100,000,000 shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding as of December 31, 2025 and 2024 | — |  |  | — |
Common stock, $.001 par value; 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 204,153,619 and 191,778,639 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 205 |  |  | 192 |
Additional paid-in-capital | 1,188,089 |  |  | 1,107,952 |
Accumulated deficit | (1,009,017) |  |  | (1,008,293) |
Total Alignment Healthcare, Inc. stockholders' equity | 179,277 |  |  | 99,851 |
Total liabilities and stockholders' equity | $ | 520,283 |  |  | $ | 425,033 |
Schedule Condensed Statements of Operations Information |
| Year Ended December 31,
| 2025 |  | 2024 |  | 2023
Revenues: |  |  |  |  |
Total revenues | $ | — |  |  | $ | — |  |  | $ | — |
Expenses: |  |  |  |  |
Selling, general, and administrative expenses | 530 |  |  | 443 |  |  | 488 |
Total expenses | 530 |  |  | 443 |  |  | 488 |
Loss from operations | (530) |  |  | (443) |  |  | (488) |
Other expenses: |  |  |  |  |
Interest expense | 15,786 |  |  | 1,700 |  |  | — |
Total other expenses | 15,786 |  |  | 1,700 |  |  | — |
Loss before income taxes | (16,316) |  |  | (2,143) |  |  | (488) |
Provision for income taxes | 16 |  |  | — |  |  | — |
Net loss of Parent Company | (16,332) |  |  | (2,143) |  |  | (488) |
Subsidiary's Net income (loss) | 15,354 |  |  | (125,928) |  |  | (147,685) |
Net loss | (978) |  |  | (128,071) |  |  | (148,173) |
Less: Net loss attributable to noncontrolling interest | (254) |  |  | (36) |  |  | (156) |
Net loss attributable to Alignment Healthcare, Inc. | $ | (724) |  |  | $ | (128,035) |  |  | $ | (148,017) |
Schedule of Condensed Statements of Cash Flows Information |
| Year Ended December 31,
| 2025 |  | 2024 |  | 2023
Operating Activities: |  |  |  |  |
Net loss attributable to Alignment Healthcare, Inc. | $ | (724) |  |  | $ | (128,035) |  |  | $ | (148,017) |
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |
Equity in loss of subsidiary | (15,100) |  |  | 125,892 |  |  | 147,529 |
Amortization of debt issuance costs | 1,761 |  |  | 220 |  |  | — |
Due to subsidiary | 14,063 |  |  | 1,923 |  |  | 488 |
Net cash provided by operating activities | — |  |  | — |  |  | — |
Investing Activities: |  |  |  |  |
Investment in Subsidiary | (18,068) |  |  | (321,525) |  |  | — |
Net cash used in investing activities | (18,068) |  |  | (321,525) |  |  | — |
Financing Activities: |  |  |  |  |
Shares withheld net of restricted stock | — |  |  | (350) |  |  | — |
Stock options exercised | 18,068 |  |  | 155 |  |  | — |
Proceeds from long-term debt | — |  |  | 330,000 |  |  | — |
Debt issuance costs | — |  |  | (8,280) |  |  | — |
Net cash provided by financing activities | 18,068 |  |  | 321,525 |  |  | — |
Net (decrease) increase in cash | — |  |  | — |  |  | — |
Cash, cash equivalents and restricted cash at beginning of period | — |  |  | — |  |  | — |
Cash, cash equivalents and restricted cash at end of period | $ | — |  |  | $ | — |  |  | $ | — |
Supplemental non-cash financing and investing activities: |  |  |  |  |
Contribution of equity to subsidiary related to equity-based compensation | $ | 62,082 |  |  | $ | 71,132 |  |  | $ | 66,835 |
Debt issuance costs in accounts payable | $ | 26 |  |  | $ | 512 |  |  | $ | — |

X
- References No definition available. + Details
Name: | srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract
Namespace Prefix: | srt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedCashFlowStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration